Niclosavir Ltd.
Niclosavir has developed
a unique platform: NicTek
Without action, antimicrobial resistance wins.
• Bovamide
Bovamide is the first product being developed using the NicTek platform.
It is being rigorously tested both in the laboratory and in the field on dairy cows for the treatment of bovine mastitis.
Safe
We prioritize animal health and safety at every stage of development, ensuring that Bovamide is a trusted solution for farmers.
Effective
Scientifically backed and proven, Bovamide will offer a powerful alternative to antibiotics, delivering measurable results.
NZ Path
Bovamide is on the pathway to becoming a registered veterinary medicine in New Zealand.
Global Path
With clear regulatory pathways defined in the US and EU, Bovamide is being positioned for international approval.
The global cost of bovine mastitis is estimated at USD 20-30 billion.
The treatment of bovine mastitis is the leading cause of antibiotic use in food-producing animals.
Bovamide is being developed as the ideal alternative to antibiotics.
The global cost of treating bovine mastitis with antibiotics is estimated at USD 1.8 billion.
Bovamide will be a world-first approach to a global problem.
Safe, effective, and sustainable alternative to antibiotics.
Antimicrobial resistance threatens modern medicine, together we can change that.